AI 탑재 혈액 분석기 시장 규모, 점유율 및 동향 분석 보고서 : 장비 유형별, 검사 유형별, 도입 형태별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

AI-enabled Hematology Analyzer Market Summary

The global AI-enabled hematology analyzer market size was valued at USD 249.7 million in 2025 and is projected to grow from USD 269.2 million in 2026 to USD 501.0 million by 2033, at a CAGR of 9.3% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 39.8% in 2025. The market growth is primarily driven by the increasing adoption of AI-driven hematology diagnostics to enhance laboratory efficiency, growing demand for automated digital cell morphology and standardized hematology workflows, and expanding deployment of AI-enabled hematology testing across point-of-care and decentralized care settings.

AI-enabled analyzers are increasingly supporting automated cell identification, classification, morphology assessment, and integration with broader hematology workflows, helping laboratories reduce dependence on manual microscopy, improve workflow efficiency, and optimize the utilization of skilled laboratory personnel.

Furthermore, growing availability of compact and AI-powered hematology analyzers for near-patient testing is extending hematology diagnostics beyond centralized laboratories into oncology centers, outpatient clinics, pharmacies, and home-based monitoring settings, further supporting market expansion.

Global AI-enabled Hematology Analyzer Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented AI-enabled hematology analyzer market report based on analyzer type, analysis type, deployment, end use and region.

• Analyzer Type Outlook (Revenue, USD Million, 2021 - 2033)
• AI-enabled Automated Hematology Analyzers
• AI-enabled Digital Cell Morphology Analyzers
• Analysis Type Outlook (Revenue, USD Million, 2021 - 2033)
• Complete Blood Count & WBC Differential
• Peripheral Blood Smear Analysis
• Body Fluid Analysis
• Bone Marrow Aspirate Analysis
• Deployment Outlook (Revenue, USD Million, 2021 - 2033)
• Standalone Systems
• Integrated Hematology Workcells
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Hospital Laboratories
• Independent Diagnostic Laboratories
• Hematology & Oncology Centers
• Other Clinical Settings
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Analyzer Type Segment
  • 1.2.2. Analysis Type Segment
  • 1.2.3. Deployment Segment
  • 1.2.4. End use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Global AI-enabled Hematology Analyzer Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing Adoption of AI-Driven Hematology Diagnostics to Enhance Laboratory Efficiency
    • 3.2.1.2. Rising Demand for Automated Digital Cell Morphology and Precision Diagnostics
    • 3.2.1.3. Growing Investments in Laboratory Automation and Digital Healthcare Infrastructure
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Stringent Clinical Validation Requirements and High Regulatory Complexity
    • 3.2.2.2. High Capital Investment and Complex Laboratory Integration
  • 3.2.3. Market opportunity analysis
• 3.3. Global AI-enabled Hematology Analyzer Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  • 3.3.2. PESTLE Analysis

Chapter 4. Global AI-enabled Hematology Analyzer Market: Analyzer Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global AI-enabled Hematology Analyzer Market Analyzer Type Movement Analysis
• 4.3. Global AI-enabled Hematology Analyzer Market Size & Trend Analysis, by Analyzer Type, 2021 to 2033 (USD Million)
• 4.4. AI-enabled Automated Hematology Analyzers
  • 4.4.1. AI-enabled Automated Hematology Analyzers market estimates and forecasts 2021 to 2033, (USD Million)
• 4.5. AI-enabled Digital Cell Morphology Analyzers
  • 4.5.1. AI-enabled Digital Cell Morphology Analyzers market estimates and forecasts 2021 to 2033, (USD Million)

Chapter 5. Global AI-enabled Hematology Analyzer Market: Analysis Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global AI-enabled Hematology Analyzer Market Analysis Type Movement Analysis
• 5.3. Global AI-enabled Hematology Analyzer Market Size & Trend Analysis, by Analysis Type, 2021 to 2033 (USD Million)
• 5.4. Complete Blood Count & WBC Differential
  • 5.4.1. Complete Blood Count & WBC Differential market estimates and forecasts 2021 to 2033, (USD Million)
• 5.5. Peripheral Blood Smear Analysis
  • 5.5.1. Peripheral Blood Smear Analysis market estimates and forecasts 2021 to 2033, (USD Million)
• 5.6. Body Fluid Analysis
  • 5.6.1. Body Fluid Analysis market estimates and forecasts 2021 to 2033, (USD Million)
• 5.7. Bone Marrow Aspirate Analysis
  • 5.7.1. Bone Marrow Aspirate Analysis market estimates and forecasts 2021 to 2033, (USD Million)

Chapter 6. Global AI-enabled Hematology Analyzer Market: Deployment Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global AI-enabled Hematology Analyzer Market Deployment Movement Analysis
  • 6.2.1. Global AI-enabled Hematology Analyzer Market Size & Trend Analysis, by Deployment, 2021 to 2033 (USD Million)
• 6.3. Standalone Systems
  • 6.3.1. Standalone Systems market estimates and forecasts 2021 to 2033, (USD Million)
• 6.4. Integrated Hematology Workcells
  • 6.4.1. Integrated Hematology Workcells market estimates and forecasts 2021 to 2033, (USD Million)

Chapter 7. Global AI-enabled Hematology Analyzer Market: End-use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global AI-enabled Hematology Analyzer Market End-use Movement Analysis
  • 7.2.1. Global AI-enabled Hematology Analyzer Market Size & Trend Analysis, by End-use, 2021 to 2033 (USD Million)
• 7.3. Hospitals & Hospital Laboratories
  • 7.3.1. Hospitals & Hospital Laboratories market estimates and forecasts 2021 to 2033, (USD Million)
• 7.4. Independent Diagnostic Laboratories
  • 7.4.1. Independent Diagnostic Laboratories market estimates and forecasts 2021 to 2033, (USD Million)
• 7.5. Hematology & Oncology Centers
• 7.6. Hematology & Oncology Centers market estimates and forecasts 2021 to 2033, (USD Million)
• 7.7. Other Clinical Settings
• 7.8. Other Clinical Settings market estimates and forecasts 2021 to 2033, (USD Million)

Chapter 8. AI-enabled Hematology Analyzer Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2021 to 2033, (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2021 to 2033, (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2021 to 2033, (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2021 to 2033, (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2021 to 2033, (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2021 to 2033, (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2021 to 2033, (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2021 to 2033, (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2021 to 2033, (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2021 to 2033, (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2021 to 2033, (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2021 to 2033, (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2021 to 2033, (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2021 to 2033, (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2021 to 2033, (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2021 to 2033, (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2021 to 2033, (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2021 to 2033, (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2021 to 2033, (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2021 to 2033, (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033, (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2021 to 2033, (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033, (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Share Analysis, 2025
• 9.4. List of Key Certification Providers/Scheme Owners
• 9.5. Company Profiles/Listing
  • 9.5.1. Sysmex Corporation
    • 9.5.1.1. Company overview
    • 9.5.1.2. Financial performance
    • 9.5.1.3. Product benchmarking
    • 9.5.1.4. Strategic initiatives
  • 9.5.2. CellaVision
    • 9.5.2.1. Company overview
    • 9.5.2.2. Financial performance
    • 9.5.2.3. Analyzer Type benchmarking
    • 9.5.2.4. Strategic initiatives
  • 9.5.3. Mindray
    • 9.5.3.1. Company overview
    • 9.5.3.2. Financial performance
    • 9.5.3.3. Product benchmarking
    • 9.5.3.4. Strategic initiatives
  • 9.5.4. Scopio Labs
    • 9.5.4.1. Company overview
    • 9.5.4.2. Financial performance
    • 9.5.4.3. Product benchmarking
    • 9.5.4.4. Strategic initiatives
  • 9.5.5. Ozelle
    • 9.5.5.1. Company overview
    • 9.5.5.2. Financial performance
    • 9.5.5.3. Product benchmarking
    • 9.5.5.4. Strategic initiatives
  • 9.5.6. SigTuple Technologies Pvt. Ltd.
    • 9.5.6.1. Company overview
    • 9.5.6.2. Financial performance
    • 9.5.6.3. Product benchmarking
    • 9.5.6.4. Strategic initiatives
  • 9.5.7. PixCell Medical
    • 9.5.7.1. Company overview
    • 9.5.7.2. Financial performance
    • 9.5.7.3. Product benchmarking
    • 9.5.7.4. Strategic initiatives
  • 9.5.8. Thermo Fisher Scientific Inc.
    • 9.5.8.1. Company overview
    • 9.5.8.2. Financial performance
    • 9.5.8.3. Product benchmarking
    • 9.5.8.4. Strategic initiatives
  • 9.5.9. Shenzhen Dymind Biotechnology Co., Ltd.
    • 9.5.9.1. Company overview
    • 9.5.9.2. Financial performance
    • 9.5.9.3. Product benchmarking
    • 9.5.9.4. Strategic initiatives
  • 9.5.10. Siemens Healthineers AG
    • 9.5.10.1. Company overview
    • 9.5.10.2. Financial performance
    • 9.5.10.3. Product benchmarking
    • 9.5.10.4. Strategic initiatives